IlluminaILMN
About: Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2023 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Employees: 9,300
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
5% less repeat investments, than reductions
Existing positions increased: 263 | Existing positions reduced: 277
2% less funds holding
Funds holding: 771 [Q1] → 754 (-17) [Q2]
3.67% less ownership
Funds ownership: 91.83% [Q1] → 88.16% (-3.67%) [Q2]
14% less first-time investments, than exits
New positions opened: 106 | Existing positions closed: 123
18% less funds holding in top 10
Funds holding in top 10: 11 [Q1] → 9 (-2) [Q2]
27% less capital invested
Capital invested by funds: $20B [Q1] → $14.7B (-$5.3B) [Q2]
30% less call options, than puts
Call options by funds: $171M | Put options by funds: $243M
Research analyst outlook
17 Wall Street Analysts provided 1 year price targets over the past 3 months
17 analyst ratings
Leerink Partners | 39%upside $200 | Outperform Maintained | 17 Oct 2024 |
HSBC Shubhangi Gupta 0 / 0 met price target | 25%upside $180 | Buy Upgraded | 17 Oct 2024 |
Barclays Luke Sergott 50% 1-year accuracy 24 / 48 met price target | 6%downside $135 | Equal-Weight Maintained | 15 Oct 2024 |
RBC Capital Conor McNamara 55% 1-year accuracy 18 / 33 met price target | 76%upside $252 | Outperform Reiterated | 10 Oct 2024 |
Argus Research Jasper Hellweg 83% 1-year accuracy 5 / 6 met price target | 5%upside $150 | Buy Upgraded | 28 Aug 2024 |
Financial journalist opinion
Based on 8 articles about ILMN published over the past 30 days